Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease.

导出 OA

翻译打印收藏纠错

作者： Ja Min,Byun ^[1] ; Chang-Ki,Min ^[2] ; Kihyun,Kim ^[3] ; Soo-Mee,Bang ^[4] ; Je-Jung,Lee ^[5] ; Jin Seok,Kim ^[6] ; Sung-Soo,Yoon ^[1] ; Youngil,Koh ^[7]

作者单位： Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, 101 Daehak-Ro, Jongno-Gu, Seoul, 03080, Korea. ^[1] Department of Hematology, Seoul St. Mary's Hematology Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea. ^[2] Division of Hematology/Oncology, Department of Medicine, Sungkyunkwan University School of Medicine Samsung Medical Center, Seoul, Korea. ^[3] Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea. ^[4] Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Hwasun, Korea. ^[5] Division of Hematology, Department of Internal Medicine, Yonsei University College of Medicine, Severance Hospital, Seoul, Korea. ^[6] Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, 101 Daehak-Ro, Jongno-Gu, Seoul, 03080, Korea. go01@snu.ac.kr. ^[7]

关键词 DCEP Daratumumab Extramedullary multiple myeloma Multiple myeloma Relapse/refractory